Patheon has entered into a development contract with Inhibrx, a biologic immunotherapeutic company focused on developing treatments in oncology, infectious disease, and inflammatory conditions.

As part of the agreement, Patheon will develop production processes at its Princeton, New Jersey, facility and will manufacture products at its Brisbane, Australia, location in support of a pipeline of future programs with Inhibrx. The initial development work will focus on establishing platform processes for Inhibrx's cell lines.

The Brisbane facility is focused on clinical and commercial biologic-based drug substance production. Patheon also has biologics sites in St. Louis, Missouri, Princeton, N.J., and Groningen, the Netherlands.

Source: Patheon